This week, Stanford scientists may have quietly cracked the code on a side-effect-free Ozempic alternative, a members-only peptide club just launched with serious VC backing, and sprinting to catch the bus might be more productive than you thought. Let's get into it.

Let's get into it.

Researchers at Stanford Medicine have identified a molecule called BRP that may suppress appetite like Ozempic—but without the usual side effects.

Instead of affecting the whole body like GLP-1 drugs, BRP works more precisely by targeting the brain’s appetite control center. In early animal studies, it cut food intake by up to 50% and led to fat loss—without causing nausea, sluggishness, or behavioral changes.

It’s still very early (no human trials yet), and the “natural Ozempic” hype is getting ahead of the science. But if it holds up, BRP could point to a more targeted, better-tolerated future for weight loss treatments.

Big insight: The next wave of obesity drugs may work smarter—not stronger.

A new player in the peptide space, Protocole, has launched with $6M in seed funding led by Rare Capital, aiming to bring structure to a fast-growing but largely unregulated market where users often rely on gray-market sources.

The platform offers a referral-only, clinician-guided model: users complete an intake, receive personalized peptide protocols for goals like recovery or longevity, and get ongoing access to licensed medical professionals, with treatments fulfilled through regulated pharmacies.

The bigger play is timing. As regulation tightens and peptides shift from underground biohacking to mainstream care, Protocole is positioning itself as the infrastructure layer for safe, standardized access—turning a fragmented “Wild West” category into a premium, trust-first experience.

A major study in the UK Biobank, published in the European Heart Journal and covered by CNN this week, tracked nearly 96,000 people over nine years and found something simple: just a small amount of vigorous activity can significantly lower disease risk.

Participants who spent as little as ~4% of their activity doing higher-intensity movement saw major benefits—including up to 63% lower dementia risk and 50% lower cardiovascular disease risk. That doesn’t mean extreme training—short bursts like brisk walking, sprinting for a bus, or climbing stairs can count.

There’s a caveat: the study is observational, so it shows strong correlation, not direct causation. But the consistency and scale of the data make the signal hard to ignore.

The takeaway: it’s not about working out longer—it’s about adding a few minutes that actually push your limits.

Stanford's BRP molecule reminded us that the most interesting breakthroughs often come from looking at what the body already makes, not what we can synthesize from scratch. Nature, it turns out, might be the best R&D department there is. 🧬

Now go sprint for four and a half minutes. Your hypothalamus will thank you.

Stay sharp,
The Wellness Radar Team

We Rated Every Youtuber HEALTH Product! (Tier List)

Got two minutes? We’d love your quick feedback to make Wellness Radar even better—more stories you care about, fewer you don’t.
👉 Click Here to take the short survey